Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
Clinical trial NCT05158140 · COMPLETED
Trial details
- NCT number
- NCT05158140
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-12
- Primary completion
- 2023-02-21
- Enrollment
- 850
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.